 Healio | Drug combination acts against aggressive chronic lymphocytic leukemia Outcome Magazine (blog) 12/10/2012 A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson ... Combination of ibrutinib and rituximab produced high response rates in high ... Ibrutinib Effective and Safe Treatment Option in CLL Investigational agent targets gene signaling pathways to improve response for ... |
